Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
The evidence Researchers evaluated veterans with type 2 diabetes who were already receiving metformin and initiated either semaglutide or an SGLT2 inhibitor as second-line therapy
Understanding the differences in the mechanism of action and potential side effects between the two medications is crucial for a smooth transition
Additional methodological details, including model specification and sensitivity analyses, are provided in the supplementary material
Consultation with an endocrinologist or obesity medicine specialist is appropriate when first-line management with tirzepatide does not produce expected results
JAMA: the journal of the American Medical Association 302, 412 (2009)
US$ 20.82
US$ 29.73
US$ 27.34
US$ 25.78
US$ 26.48
US$ 27.24
US$ 21.09
US$ 27.06
